Narrow-Moat Sobi's Strategic Portfolio Drives Strong Growth as Pipeline Advances

As recently as 2016, Swedish Orphan Biovitrum, or Sobi, was largely a specialty pharmaceutical firm in-licensing rights to market drugs in Europe. Since then, the successful launches of hemophilia drugs Elocta and Alprolix in Europe and other international markets, and several acquisitions and collaborations have expanded Sobi's business geographically (to the US) and into new therapeutic areas (in immunology and hematology). Sobi's acquired immunology drugs (Astra's Synagis and Beyfortus, Novimmune's Gamifant, Apellis' Aspaveli) and hematology drugs (Dova's platelet drug Doptelet, ADC's blood cancer drug Zynlonta, and CTI's Vonjo) help drive long-term growth prospects. We think Sobi is taking the right steps to diversify and boost long-term growth, and that the firm warrants a narrow moat rating.